Craft

Teva Pharmaceuticals

Stock Price

$18.4

2024-10-29

Market Capitalization

$20.8 B

2024-10-28

Revenue

$17.3 B

FY, 2025

Teva Pharmaceuticals Summary

Company Summary

Overview
Teva Pharmaceuticals is a global pharmaceutical company. Its product and service portfolio includes generic medicines, biopharmaceuticals, specialty medicines, OTC products, a distribution business, API and contract manufacturing. The company develops, manufacture,s and sell generic medicines in a variety of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. Teva offers a range of basic chemical entities, as well as specialized product families, such as sterile products, hormones, high-potency drugs, and cytotoxic substances, in both parenteral and solid dosage forms.
Type
Public
Status
Active
Founded
1901
HQ
Petah Tikva, IL | view all locations
Website
http://www.tevapharm.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Richard Daniell

    Richard Daniell, Executive Vice President, European Commercial

  • Eric Drapé

    Eric Drapé, Executive Vice President, Global Operations

  • Hafrun Fridriksdottir

    Hafrun Fridriksdottir, Executive Vice President, Global R&D

  • Eli Kalif

    Eli Kalif, Executive Vice President, Chief Financial Officer (CFO)

Operating MetricsView all

Active Pharmaceutical Ingredients Production Facilities

17
5.6%

FY, 2019

Tablets and Capsules Produced

73B
8.8%

FY, 2019

Finished Dosage and Packaging Manufacturing Facilities

47
14.5%

FY, 2019

LocationsView all

83 locations detected

  • Petah Tikva, Center District HQ

    Israel

    5 Basel St

  • Parsippany-Troy Hills, NJ

    United States

    400 Interpace Pkwy #3, Parsippany

  • Villa Adelina, Buenos Aires

    Argentina

    Juan José Castelli 6701

  • Macquarie Park, NSW

    Australia

    37 Epping Rd

  • Minsk, Minskaja voblasć

    Belarus

    Sverdlova 2

  • Antwerpen, Vlaanderen

    Belgium

    Laarstraat 16

and 77 others

Teva Pharmaceuticals Financials

Summary Financials

Revenue (Q1, 2026)
$4.0B
Gross profit (Q1, 2026)
$2.0B
Net income (Q1, 2026)
$369.0M
Cash (Q1, 2026)
$3.7B
EBIT (Q1, 2026)
$652.0M
Enterprise value
$34.0B

Footer menu